BrainStorm Cell Therapeutics Inc. announced the promotion of Dr. Stacy Lindborg to the role of co-chief executive officer. This promotion launches a targeted capability build which will be led by Dr. Lindborg, to hire and bring expertise inside BrainStorm, preparing for success. Dr. Lindborg, who joined the company in 2020 and is based in the U.S., brings to her expanded role more than 25 years of pharmaceutical industry experience in R&D, strategy development, regulatory, and analytics.

She will work alongside Mr. Chaim Lebovits, who is retaining his position as President and CEO. In addition, Dr. Ralph Kern will retire from his current role as President and Chief Medical Officer in January 2023 and will continue to support BrainStorm as part of the company's Scientific Advisory Board. Stacy Lindborg, Ph.D. joined the company in 2020 serving most recently as Executive Vice President and Chief Development Officer.

Her experience includes senior roles at Eli Lilly & Company and Biogen. At Biogen she was Vice President, Analytics and Data Science, and managed a team that contributed in material ways towards the regulatory approval of products such as Spinraza®. At Eli Lilly & Company, she held positions of increasing responsibility including Head of R&D Strategy, where she was responsible for characterizing the productivity of the portfolio and driving key R&D strategy projects including the annual R&D Long-Range Plan.

She was also Leader of Zyprexa Product Management in which she was responsible for R&D, Commercial and Manufacturing plans. She was accountable for driving market share through product differentiation, global registration and launching of an injectable form of Zyprexa, working through regulatory manufacturing inspections and 483 citations. Dr. Lindborg holds a Ph.D. in statistics from Baylor University.

She serves on the Scientific Advisory Board of biotechnology and technology companies and on the board of directors of Imunon Inc. and the Massachusetts Down Syndrome Congress.